Arix Bioscience Plc - Board changes
("Arix") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announced that Dr has been appointed to the Board as a Non-Executive Director with effect from 17 . Upon appointment, Naseem will become a member of the Remuneration Committee. Dr will be retiring from the Board on the same date., :
“We are very pleased to have Naseem join the Board. His broad experience in life sciences, corporate development and venture capital, coupled with his strong industry network, will be invaluable in guiding Arix’s vision of building a broad portfolio of innovative young biotech companies to deliver important new therapies for patients and substantial value to our investors, Chairman of Arix,
“On behalf of the Board, I would also like to thank Franz for the important role he has played in guiding the early development of Arix. We wish him the very best and look forward to staying in touch.”
“I’m very pleased to join the . The company has built an impressive portfolio of innovative young companies and I look forward to working with the Executive team and Board to continue this development and deliver substantial value for patients and investors."Dr added:
Dr brings over 25 years of broad life sciences experience, having held senior positions in major healthcare businesses. Previous roles include Chief Scientific Officer of Smith and Nephew Plc, Senior Vice President of Business Development at Biogen and Vice President of at Genzyme. He is currently CEO of GMP-Orphan and a Venture Partner at Advent Life Sciences. Naseem is a qualified medical doctor, from the , , and an MBA from the , .
For more information on Arix, please contact:
, Head of Investor Relations
+44 (0)20 7290 1072
T: +44 (0) 203 950 9144
is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
Quick facts: Arix Bioscience PLC
Market Cap: £81.33 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE